荆花胃康联合三联疗法在Hp感染患者中的临床观察  

Clinical Observation of Jinghua Weikang Combined with Triple Therapy in Patients with Hp Infection

作　　者：苗瑞 布琼 彭博[1] 杨成昆 鲍秀琦[1] Miao Rui;Bu Qiong;Peng Bo;Yang Chengkun;Bao Xiuqi(First Hospital Affiliated to Jiamusi University,Jiamusi 154003,China)

机构地区：[1]佳木斯大学附属第一医院,黑龙江佳木斯154003

出　　处：《广东化工》2020年第4期49-50,共2页Guangdong Chemical Industry

摘　　要：目的:探讨荆花胃康联合三联疗法在Hp(幽门螺杆菌)感染患者中的临床观察。方法:选取佳木斯大学附属第一医院收治的136例幽门螺杆菌感染慢性胃炎患者作为研究对象,随机分为两组,实验组68例,对照组68例。实验组及对照组均服用雷贝拉唑,阿莫西林,克拉霉素传统的三联疗法,实验组该基础上加上荆花胃康进行治疗。对照组联合应用用安慰剂治疗,两组患者均连续服药时间为4周。治疗结束后停药,1个月后复查14C呼气试验。观察比较、幽门螺杆菌清除率、临床总有效率及、消化道症状,治疗期间药物不良反应率,结果:比较两组患者。治疗后实验组的幽门螺杆菌清除率明显高于对照组(P<0.05),总有效率实验组为96%,对照组为84%,2组比较,差异有统计学意义(P<0.05)。实验组与对照组患者腹胀、上腹痛、纳差、嗳气等消化道症状评分均较治疗前明显降低(P<0.05),并且实验组各项症状评分均低于对照组(P<0.05)。两组患者在服药治疗过程中都未发生严重的不良反应,一般不良反应率比较差异无统计学意义(P>0.05)。结论:荆花胃康联合传统三联疗法治疗幽门螺杆菌所感染的慢性胃炎患者,可以显著提升临床总有效率,降低临床消化道症状率,药效发挥迅速,不良反应少,提高临床疗效,提升患者生活质量。Objective: To explore the clinical observation of Jinghua Weikang combined with triple therapy in patients with H. pylori infection. Methods: 136 patients with Helicobacter pylori-infected chronic gastritis treated in the First Affiliated Hospital of Jiamusi University were selected as the research objects and randomly divided into two groups, 68 in the experimental group and 68 in the control group. Both the experimental group and the control group were treated with the traditional triple therapy of rabeprazole, amoxicillin, and clarithromycin. The experimental group was treated with Jinghuaweikang. The control group was treated with a combination of placebo, and the patients in both groups were treated continuously for 4 weeks. The drug was discontinued after treatment, and the 14 C breath test was reviewed one month later. Observation and comparison, H. pylori clearance rate, total clinical effectiveness and digestive tract symptoms, and adverse drug reaction rates during treatment. Results: The two groups of patients were compared. After treatment, the H. pylori clearance rate in the experimental group was significantly higher than that in the control group(P<0.05). The total effective rate was 96% in the experimental group and 84 % in the control group. The difference between the two groups was statistically significant(P<0.05). The scores of gastrointestinal symptoms such as abdominal distension, epigastric pain, anorexia, and belching were significantly lower in the experimental group and the control group than before treatment(P<0.05), and the scores of all symptoms in the experimental group were lower than the control group(P<0.05). There were no serious adverse reactions in the two groups of patients during the medication, and there was no significant difference in the general adverse reaction rate(P>0.05). Conclusion: Jinghua Weikang combined with traditional triple therapy for chronic gastritis patients infected with Helicobacter pylori can significantly improve the total clinical effectiveness, reduc

关 键 词：幽门螺杆菌感染慢性胃炎 荆花胃康 PPI三联疗法 

分 类 号：TQ[化学工程]